-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Atherosclerosis is the leading cause of
cardiovascular disease worldwide, including in China.
Primary prevention by lowering lipids allows the development of
atherosclerosis to be avoided.
Carotid endartere-medial thickness (CIMT) is a validated measurement of atherosclerosis that is used as the primary outcome and surrogate endpoint
of cardiovascular disease events in intervention studies.
This randomized, double-blind, placebo-controlled, multicenter, parallel-group study evaluated the effect
of rosuvastatin 20 mg/day compared with placebo on the progression of CIMT in the Chinese of subclinical arteriosclerosis over a 104-week period.
The primary endpoint was the annualized rate
of change of the maximum CIMT mean measured seven times each from each of the 12 carotid artery sites (proximal and distal walls of the left and right common carotid arteries, carotid bulbs, and internal carotid arteries) during the study period.
Secondary endpoints included changes in CIMT and changes
in lipid parameters at different arterial sites.
Safety has also been assessed
.
Results showed that participants were randomized (1:1) to receive rosuvastatin (n=272) or placebo (n=271).
The baseline characteristics are well balanced
between the groups.
The mean change in maximal CIMT at 12 carotid artery sites was 0.
0038 mm/year (95% CI, -0.
0023 to 0.
0100) in the rosuvastatin group compared with 0.
0142 mm/year (95% CI, 0.
0080-0.
0204) and -0.
0103 mm/year (95% CI, -0.
0191 to -0.
0016; P = 0.
020)
in the placebo group.
For the CIMT secondary endpoint, the results were broadly consistent
with the primary endpoint.
Rosuvastatin has clinically relevant improvements
in lipid parameters.
In summary, rosuvastatin 20mg/d can significantly reduce the progression of CIMT in Chinese adults with subclinical atherosclerosis within 2 years and is well
tolerated.
References:
Rosuvastatin Slows Progression of Carotid Intima-Media Thickness: The METEOR-China Randomized Controlled Study.
https://doi.
org/10.
1161/STROKEAHA.
120.
031877Stroke.
2022; 53:3004–3013
